Evidence map›Paper›PMID 42262506›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2026

Inhaled pattern recognition receptor agonists promote inducible epithelial resistance against murine betacoronavirus disease.

Michael K Longmire, Jezreel Pantaleón García, Raquel Alonso Becerra, Valerie B Oren, Oanh N Hoang, Jania Foncerrada Lizaola, Scott E Evans

Abstract read
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael K LongmireDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0000-0002-1591-0264
Jezreel Pantaleón GarcíaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0000-0002-9647-2584
Raquel Alonso BecerraDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0009-0001-4797-6719
Valerie B OrenDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0009-0009-1343-0257
Oanh N HoangDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0000-0001-5304-585X
Jania Foncerrada LizaolaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0009-0001-0504-2395
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, United States.ORCID 0000-0003-4503-0644

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Inducible epithelial antiviral resistance to prevent asthmaDP2HL123229 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2013 to 2013
$2.4M
Epithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M
HHS | NIH | National Cancer Institute (NCI) P30CA016672NCI NIH HHS P30 CA016672NHLBI NIH HHS DP2 HL123229NHLBI NIH HHS R01 HL117976NHLBI NIH HHS R35 HL144805
6 · The paper itself

Abstract

Coronaviruses can cause serious disease in humans and animals. They are often difficult to study due to the variability of the disease as well as safety concerns related to biosafety requirements. Here, we use a biological safety level (BSL) 2-compatible murine betacoronavirus (MHV-A59), which infects multiple organs, to study the respiratory phase of disease and subsequent systemic dissemination. We asked whether inducible epithelial resistance, activated by the combination of pattern recognition receptor agonists Pam2CSK4 (Pam2), synthetic diacylated lipopeptide, + oligodeoxynucleotide (ODN) M362, can limit both pulmonary infection and systemic spread of disease. Prophylactic exposure with Pam2 + ODN improves survival and reduces extrapulmonary viral burden, including in the liver, consistent with limited systemic spread. Stopping the infection at the level of the lungs is associated with improved physiological outcomes and increased protection for the mice. We further characterize the response of the epithelial cells to infection and treatment and demonstrate modulation of epithelial gene expression, including attenuation of virus-induced responses, to better understand the mechanisms of protection and how these responses may be leveraged against future infectious agents.

Indexed as

Epithelial CellsLipopeptidesReceptors, Pattern RecognitionAnimalsFemaleLungMiceMice, Inbred C57BLToll-Like Receptor AgonistsLipopeptidesPam2CSK4 lipopeptideReceptors, Pattern RecognitionToll-Like Receptor Agonistsanimal disease modelscoronaviridae infectionsepithelial cellsinnate immunityrespiratory tract infections

Identifiers

PMID42262506
PMCPMC13334886

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.